Inspiring your team. Growing your business. Staying in compliance. Financial planning. The best decisions your peers have made. Those and more are part of APC's 2021 Compounding Pharmacy Owner Summit, coming March 25–27, 2021 IN PERSON at The Westin at Jekyll Island, Georgia.
The National Community Pharmacists Association has had enough: It's suing HHS over DIR fees.
Last week, FDA announced that it was reopening the comment period for it’s proposed updated 503B Bulks List — the “bulk drug substances (active pharmaceutical ingredients) that FDA has considered and proposes to include or not include on the list of bulk drug substances for which there is a clinical need.” Comments can now be submitted until February 8, 2021, and APC is considering commenting. Simply put: We welcome member input about what should be the substance of those comments. Nothing formal (on your end); all you need to do is send an email to scott@a4pc.org.
If you precept pharmacy students, we’ve got an offer for you — one we think will be attractive to students with an interest in compounding.
Watch your mailbox! Coming soon is Pharmacy Compounding Leader, the first issue of our new newsletter showcasing the updated Pharmacy Compounding Professional’s Code of Ethics.
We all know compounding is under-represented on state boards of pharmacy, and it’s important that state pharmacy boards hear what compounders have to say. That’s where you come in.
Do you still have to file sales-tax permits in each state for NONprescription drugs or supplements? It depends.
APC has not only met, but well exceeded our initial $250,000 fundraising goal for our cBHT Media Campaign.
Best practices. ETHICAL practices. That's the focus of APC's EduCon Virtual 2021. It's coming fast — February 4 - 5. Get info, get registered, and get your team to go: A4PC.org/educon2021.
Be sure to read this wonderful story about compounding pharmacist Eddie Levin who lost his job — and whose neighbors came to the rescue.
PBMs have notoriously been a black box of pricing, but that's starting to change. Check out APC's upcoming CE webinar (next Tuesday!), "State and Federal Regulation of PBMs – Legislative and Regulatory Efforts to Open the Black Box of PBMs."
2021 has new opportunities for you to serve and advance your profession. Lend your expertise as a member of a 2020 APC volunteer committee, the workhorses of the alliance — help develop programming, chase possibilities, recommend policy, and more.
A big thank you to the 32 members of Congress who signed a letter to FDA Commissioner Stephen Hahn — a letter urging that the agency not base decisions about compounded hormone therapy on the flawed NASEM study.
Paper prescriptions are well on their way out, so your e-script knowledge needs to be 100 percent up to date. NCPDP Script 2017071 is the 800-pound gorilla of electronic prescribing, and you’ll want to know it backwards and forwards. APC’s new live webinar, E-Prescribing in Compounding, will help you do just that.
Congrats to APC member Diana Harshbarger (TN-1), who will become the first compounder in Congress with her victory Tuesday. (Buddy Carter, GA-1, currently the only pharmacist in Congress, was reelected as well.)
It's the 500-lb gorilla of electronic prescribing, and you'll want to know it backwards and forwards. It's NCPDP Script 2017071, and APC's new live webinar, E-Prescribing in Compounding, will help you do just that.
This week the Pharmacy Compounding Foundation voted to take a leadership role in the effort to protect cBHT. The Foundation board approved substantial funding for an objective, third-party, comprehensive analysis of the NASEM cBHT study.
Until it’s legal, don’t compound peptides that don’t meet 503A active ingredient criteria.
California's Board of Pharmacy is considering a rather overzealous attempt to limit animal compounding from bulks, and APC is happy to support our friends at the California Pharmacists Association with a letter to the BoP opposing those changes.
Congress had one idea about deregulating hemp, but the DEA has its own. The result is confusion about the legality of hemp and CBD — and who regulates what.
"I suspect we’re likely to see litigation by compounding pharmacies adversely affected by the MOU. We could even see litigation by states. FDA could have worked with stakeholders on this and created a workable MOU, but as ever, it kept its own counsel, and here we are."
Check out the latest entry in FDA Law Blog: "Lemonade from Lemons: Fairness in FDA Enforcement Actions." It's about executive order 13924, which says federal agencies "shall consider" fairness in enforcement actions. How might that apply to FDA?
Specifically the Rutledge v PCMA case? The practices of 1000s of community pharmacies and their patients, that's what. Our allies explain: "States vs. PBMs at the Supreme Court: What’s at Stake for Patients."
A big thank you to all the members of Congress who signed onto the joint letter to FDA — led by Reps. Norcross, Pocan, and Yoho — asking that the agency withdraw GFI #256 on animal compounding. (Click here to see the list and read the letter.)
APC is loving this powerful op-ed from Congressman Griffith about the FDA's MOU. It makes important patient access and economic arguments against the MOU as presently proposed. Please share and spread the word (and a thank-you to the congressman wouldn't hurt, either).
The Tricare recoupment fiasco faced by hundreds of pharmacies across the country appears to be nearing its end, with a victory for pharmacists in sight.
Join the board of the Pharmacy Compounding Foundation! Help direct its mission, advance pharmacy compounding, and do more for patients. NOMINATIONS CLOSE THURSDAY, OCTOBER 15. Just click here to self-nominate!
The comment period for animal compounding GFI 256 is closing THURSDAY, October 15. As written, the draft guidance will restrict veterinary practice, increase prices of compounded drugs for animals, and put animal health at risk. Here's how you can help — but hurry!
APC's been working on the Tricare clawback issue, and we've got some pretty good news. It's too much for a quick post here, so we've scheduled a (final?) briefing call THIS WEDNESDAY, October 14, at 4:00pm EDT. Free to all, but registration required — click here to do that.
Help us collect testimonials and urge Congress to let FDA know: cBHT needs to be protected. Millions of patients are counting on us!
FOLLOW US
